0001387131-12-003372.txt : 20121030 0001387131-12-003372.hdr.sgml : 20121030 20121030165120 ACCESSION NUMBER: 0001387131-12-003372 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121025 ITEM INFORMATION: Other Events FILED AS OF DATE: 20121030 DATE AS OF CHANGE: 20121030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26372 FILM NUMBER: 121169058 BUSINESS ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 310 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 310 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 adamis-8k_102512.htm CURRENT REPORT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 25, 2012

ADAMIS PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

Registrant’s telephone number, including area code: (858) 997-2400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

£	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On October 25, 2012 Adamis Pharmaceuticals Corporation (the “Company”) entered into a zero coupon secured promissory note (the “Note”) with The G-Max Trust (“G-Max”), evidencing a loan from G-Max to the Company (the “Loan”). We received gross proceeds of approximately $499,000. As has been previously reported, G-Max is a previous investor in the Company and holds shares of common stock and a convertible note.

The Note has a stated maturity date of six months after the date of the Note, April 25, 2013. At maturity, we agreed to repay G-Max the sum of $588,000. The Note does not have a stated interest rate so long as we repay the principal balance by the maturity date and there is no other event of default. The Note is also due and payable if we complete a financing transaction or series of transactions after the date of the Note that result in proceeds to the Company of $2,000,000 or more.

As additional consideration for the Loan, we issue to G-Max 176,400 shares of our common stock. Pursuant to the terms of a security agreement and a stock escrow agreement, we issued 700,000 shares of our common stock as collateral for the timely repayment of the Note, to be held by a third party escrow agent pursuant to the terms of the escrow agreement. If the Loan is repaid, then the collateral shares will be returned to the Company and cancelled.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ADAMIS PHARMACEUTICALS CORPORATION



Dated: October 29, 2012	By:	/s/ Robert O. Hopkins
		Name: Robert O. Hopkins
		Title: Chief Financial Officer

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

11455 El Camino Real, Suite 310

San Diego, CA

(Address of Principal Executive Offices)

(Zip Code)